How well flu, COVID-19, and other respiratory vaccines protect people in southeastern Michigan
RFA-IP-22-004:Michigan-Ford Initiative to Measure Vaccine Effectiveness (MFIVE): Seasonal Influenza, COVID-19 and Respiratory Virus Vaccines
This project checks how well seasonal flu, COVID-19, and other respiratory vaccines protect people who visit clinics for coughs, colds, or breathing problems in southeastern Michigan.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11170372 on NIH RePORTER |
What this research studies
If you take part, researchers will enroll people who come to participating outpatient clinics and testing centers with acute respiratory symptoms. They will collect swabs and blood samples and test for flu, COVID-19, RSV, and other respiratory viruses, while comparing vaccination status using a test-negative approach. The team will also analyze antibody responses and sequence viral genomes to see which virus strains are causing illness and whether vaccines are matching those strains. Enrollment focuses on clinics across multiple communities, including sites that serve populations disproportionately affected by respiratory infections.
Who could benefit from this research
Good fit: People of any age who go to participating outpatient clinics or testing centers in southeastern Michigan with symptoms of acute respiratory illness are ideal candidates.
Not a fit: People without respiratory symptoms, those not seeking care, or individuals living outside the study region are unlikely to be eligible or directly benefit from participation.
Why it matters
Potential benefit: If successful, this work could help improve vaccine recommendations and better protect people from flu, COVID-19, and other respiratory viruses.
How similar studies have performed: The U.S. Flu VE Network has successfully used this test-negative surveillance approach for years, though adding antibody testing and whole-genome sequencing expands what can be learned.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Martin, Emily Toth — University of Michigan at Ann Arbor
- Study coordinator: Martin, Emily Toth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.